Method to accelerate stem cell recruitment and homing

• US 20060110374A1
• Filed: 11/11/2005
• Published: 05/25/2006
• Est. Priority Date: 11/24/2004
• Status: Abandoned Application

• Current Assignee: Kwalata Trading Ltd.
• Original Assignee: Kwalata Trading Ltd.
• Inventors: Porat, Yael, Fulga, Valentin, Goldstein, Daniel, Czeiger, Dudy
• Application Number:
  US11/271,043
• Publication Number:
  US 20060110374A1
• Time in Patent Office: Days
• US Class Current: 424/93.700
• CPC Class Codes: A61K 2035/124 the cells being hematopoietic, bone marrow derived or blood cells
• CPC Class Codes: A61K 35/44 Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
• CPC Class Codes: C12N 5/0692 Stem cells; Progenitor cells; Precursor cells

Abstract

A method is provided for facilitating treatment of a patient, including stressing a portion of the patient to an extent sufficient to induce homing of progenitor cells to the portion of the patient. A method is additionally provided for use with tissue of a patient, including evaluating an indication of a level of stromal cell-derived factor-1 (SDF-1) in the tissue, and determining an indication of a number of stem cells in the tissue responsive to the indication of the level of SDF-1. A method is yet additionally provided for use with tissue of a patient, including evaluating an indication of a level of SDF-1 in the tissue, and determining an indication of a level of stress of a portion of the patient, responsive to the indication of the level of SDF-1. Other embodiments are also described.

Claims

1. A method for facilitating treatment of a patient, comprising stressing a portion of the patient to an extent sufficient to induce homing of progenitor cells to the portion of the patient.

2. The method according to claim 1,

comprising determining that the portion is in an ischemic state,

wherein stressing the portion comprises stressing the portion, following the determination, to an extent sufficient to augment the ischemic state.

3. The method according to claim 1, wherein stressing the portion comprises transiently augmenting a pathology of the portion of the patient.

4. The method according to claim 1, wherein the progenitor cells include endothelial progenitor cells (EPCs).

5. The method according to claim 1, wherein stressing comprises chemically stressing.

6. The method according to claim 1, wherein stressing comprises electrically stressing.

7. The method according to claim 1, wherein stressing comprises mechanically stressing.

8. The method according to claim 1, wherein stressing comprises inducing inflammation of the portion.

9. The method according to claim 1, not comprising administering the progenitor cells to the patient.

10. The method according to claim 9, comprising facilitating mobilization of the progenitor cells into peripheral blood of the patient.

11. The method according to claim 10, wherein facilitating the mobilization comprises administering a drug that mobilizes the progenitor cells.

12. The method according to claim 10, wherein facilitating the mobilization comprises increasing peripheral blood oxygen partial pressure.

13. The method according to claim 10, wherein facilitating the mobilization comprises inducing transient ischemia at a site of the patient.

14. The method according to claim 13, wherein inducing the transient ischemia at the site comprises selecting the site to include the portion of the patient.

15. The method according to claim 13, wherein inducing the transient ischemia at the site comprises selecting the site to not include the portion of the patient.

16. The method according to claim 13, wherein inducing the transient ischemia at the site comprises selecting the site to include a limb of the patient.

17. The method according to claim 1, comprising administering the progenitor cells to the patient.

18. The method according to claim 17,

wherein the administered progenitor cells comprise progenitor cells that have been enriched ex vivo from an original set of progenitor cells extracted from the patient,

and comprising, prior to administering the ex-vivo-enriched progenitor cells to the patient, facilitating mobilization of the original set of progenitor cells into peripheral blood of the patient.

19. The method according to claim 18, wherein facilitating the mobilization comprises administering a drug that mobilizes the progenitor cells.

20. The method according to claim 18, wherein facilitating the mobilization comprises increasing peripheral blood oxygen partial pressure.

21. The method according to claim 1, wherein stressing the portion comprises stressing a heart of the patient.

22. The method according to claim 21, wherein stressing the heart comprises administering a drug that affects the heart.

23. The method according to claim 22, wherein administering the drug comprises administering a tachycardia-inducing drug.

24. The method according to claim 1, wherein stressing the portion comprises stressing a brain of the patient.

25. The method according to claim 24, wherein stressing the brain comprises reducing blood flow to the brain.

26. The method according to claim 1, wherein stressing the portion comprises stressing bowel of the patient.

27. The method according to claim 26, wherein stressing the bowel comprises administering a drug that restricts blood flow to the bowel.

28. The method according to claim 26, wherein stressing the bowel comprises increasing peristalsis of the bowel to an extent sufficient to elevate a level of ischemia of the bowel.

29. A method for use with tissue of a patient, comprising:

evaluating an indication of a level of stromal cell-derived factor-1 (SDF-1) in the tissue; and

determining an indication of a number of stem cells in the tissue responsive to the indication of the level of SDF-1.

30. The method according to claim 29, wherein the tissue includes blood extracted from the patient, and wherein determining comprises determining an indication of a number of stem cells in the extracted blood.

31. The method according to claim 29, comprising diagnosing a condition of the patient responsive to the indication of the level of SDF-1.

32. The method according to claim 29, comprising increasing ex vivo a number of progenitor cells obtained from a patient blood sample that was extracted following the determining of the indication of the number of stem cells.

33. A method for use with tissue of a patient, comprising:

evaluating an indication of a level of stromal cell-derived factor-1 (SDF-1) in the tissue; and

determining an indication of a level of stress of a portion of the patient, responsive to the indication of the level of SDF-1.

34. The method according to claim 33, comprising determining a time for administration of progenitor cells to the patient, responsive to the level of stress of the portion of the patient.

35. The method according to claim 33, wherein the portion is selected from the list consisting of:

heart, bowel, limb, and brain, and wherein determining the indication comprises determining an indication of a level of stress of the selected portion.

36. The method according to claim 33, comprising determining a time for administration of progenitor cells to the patient, to a site local to the portion, responsive to the indication of the level of stress of the portion of the patient.

37. The method according to claim 36, wherein the site local to the portion is a transcatheter administration site of the progenitor cells.

38. The method according to claim 33, comprising determining a time for administration of progenitor cells to the patient, at a site remote from the portion, responsive to the indication of the level of stress of the portion of the patient.

39. The method according to claim 38, wherein the site remote from the portion is an intravenous administration site of the progenitor cells.